Cipher Pharmaceuticals Signs Exclusive License Agreement with Moberg Pharma for Commercialization of MOB-015 for Canada
Shots:
- Moberg to receive $14.6M as upfront and milestone payments of $4.6M for development and regulatory ($0.5M initial payment) and $10M on commercialization of product
- Moberg will be responsible for manufacturing the product while Cipher will take care of marketing- distribution and sales after completion of P-III trial and registration
- Moberg’s MOB-015 is a topical formulation of terbinafine- based on non-prescription nail spraying Kerasal Nail/ Emtrix. MOB-015 is currently in P-III (N= approx. 750 - 800)- being evaluated in multicentre studies including North America and EU
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
